AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2019
May 30, 2019
30849_dirs_2019-05-30_d2222b31-762a-438d-898a-8fd432acbdd5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2019-05-28
Reporting Person: Van der Ploeg Leonardus H.T. (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-05-28 | Common Stock | M | 9860 | $4.59 | Acquired | 52199 | Direct |
| 2019-05-28 | Common Stock | M | 140 | $6.14 | Acquired | 52339 | Direct |
| 2019-05-28 | Common Stock | S | 10000 | $25.38 | Disposed | 42339 | Direct |
| 2019-05-29 | Common Stock | M | 5000 | $4.59 | Acquired | 47339 | Direct |
| 2019-05-29 | Common Stock | S | 5000 | $25.51 | Disposed | 42339 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-05-28 | Employee Stock Option (Right to Buy) | $4.59 | M | 9860 | Acquired | 2025-11-16 | Common Stock (9860) | Direct |
| 2019-05-28 | Employee Stock Option (Right to Buy) | $6.14 | M | 140 | Acquired | 2027-04-04 | Common Stock (140) | Direct |
| 2019-05-29 | Employee Stock Option (Right to Buy) | $4.59 | M | 5000 | Acquired | 2025-11-16 | Common Stock (5000) | Direct |
Footnotes
F1: This transaction was executed in multiple trades at prices ranging from $25.01 to $26.10, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $25.18 to $26.02, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015.
F4: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017.